Altimmune (ALT – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s shares ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT stock is a Buy.

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Altimmune ( NASDAQ:ALT ) Full Year 2024 Results Key Financial Results Net loss: US$95.1m (loss widened by 7.5% from FY... Altimmune ( NASDAQ:ALT ) Third Quarter 2024 Results Key Financial Results ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at B. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. B.

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two ...

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.05. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average ...

Altimmune, Inc. announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso, who bring extensive experience in the biopharmaceutical industry.